OBJECTIVES: @entity299 remains a major cause of @entity204 in Japan. We have implanted autologous bone marrow-derived cells locally into the ischaemic region as a therapy in addition to coronary artery bypass grafting since 1999. We describe the outcomes of our cell therapy for @entity299 . METHODS: Eleven @entity1 underwent local implantation of bone marrow-derived cells into the ischaemic region during coronary artery bypass grafting. Clinical outcomes during the acute and chronic phases were recorded. RESULTS: In the acute phase, no adverse effects were observed. Left ventricular ejection fraction values were not significantly different before and after treatment. Seven of the 11 @entity1 showed improved blood perfusion in the area of cell therapy 1 month after treatment. In the chronic phase, 5 of 11 @entity1 exhibited improved regional blood flow 1 year after treatment. Overall survival at 1, 5 and 10 years was 100%, 83.3% and 83.3%, respectively. Freedom from major adverse cardiac and cerebrovascular events at 1, 5 and 10 years was 100%, 80.8% and 80.8%, respectively. Death from all causes or freedom from major adverse cardiac and cerebrovascular events at 1, 5 and 10 years was 100%, 64.6% and 64.6%, respectively. CONCLUSIONS: Local implantation of bone marrow-derived cells in @entity1 with @entity299 is safe and feasible. Cell therapy is a therapeutic option for otherwise untreatable @entity299 .

Short- and long-term outcomes of intramyocardial implantation of autologous bone marrow-derived cells for the treatment of XXXX .

@entity1 :: ('9606', 'Species') :: ['patients'] @entity204 :: ('MESH:D003643', 'Disease') :: ['death'] @entity299 :: ('MESH:D006331', 'Disease') :: ['ischaemic heart disease', 'Ischaemic heart disease']
@entity299 :: (MESH:D006331,Disease) :: ['ischaemic heart disease']
